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Abstract With the increase in popularity of the use of
cosmetic fillers in plastic and esthetic surgery, the possi-
bility of severe ocular complications should not be
neglected. Of the fillers used, autologous fat is the most
common to cause permanent visual deterioration, one of
the most severe complications associated with the use of
cosmetic fillers. Here we present the first report of a
complete recovery of visual acuity from an instance of
visual loss with no light perception caused by ophthalmic
artery occlusion of the right eye following autologous fat
injection in the facial area. Immediate ophthalmological
intervention and comprehensive therapy with pros-
taglandins and vinpocetine made it possible to restore
retinal perfusion and achieve complete recovery of visual
acuity. Awareness of the iatrogenic artery occlusions
associated with facial fillers and the need for immediate
treatment should be popularized among injectors to prevent
devastating consequences, such as permanent vision loss.
Level of Evidence V This journal requires that authors
assign a level of evidence to each article. For a full
description of these Evidence-Based Medicine ratings,
please refer to the Table of Contents or the online
Instructions to Authors www.springer.com/00266.
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Introduction
With the increase in popularity of the use of cosmetic fillers
in plastic and esthetic surgery, the possibility of severe
ocular complications should not be neglected. Permanent
visual deterioration, one of the most severe complications
associated with the use of cosmetic fillers, can be the result
of ophthalmic artery occlusion (OAO), generalized poste-
rior ciliary artery occlusion (generalized PCAO) with rel-
ative sparing of the central retinal artery, central retinal
artery occlusion (CRAO), localized PCAO, branch retinal
artery occlusion (BRAO) and posterior ischemic optic
neuropathy (PION). Another classification includes diffuse
occlusions (OAO, generalized PCAO, CRAO) and local-
ized occlusions (localized PCAO, BRAO, PION) [1, 2].
Autologous fat injections are associated with diffuse
occlusions, such as OAO [1] and central retinal artery
occlusion [3], and are therefore characterized by more
severe clinical symptoms and poorer visual prognosis when
compared to other facial fillers. The proposed underlying
mechanism assumes intravascular injection and retrograde
embolization of the filler, as the injected bolus may over-
come arterial pressure and move against the direction of
blood flow [3, 4]. When the injector releases the plunger,
the filler travels with blood flow and enters the ophthalmic
artery and its branches. With higher injection pressures,
filler particles may be pushed further retrograde and enter
the brain circulation, which in turn results in cerebral
infarction. Autologous fat is the most common filler type to
cause iatrogenic blindness, being responsible for almost
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48% of the cases of cosmetic filler-induced visual loss
reported in the literature up to the present [3]. Ocular
complications occur most frequently after injection to the
glabellar area, nasal region, nasolabial fold and forehead.
However, due to the complex vascular anatomy of the face,
essentially any location of the facial region may be at risk
of ocular complications. Ocular symptoms most commonly
include: sudden unilateral vision loss, ocular pain and
headache, which are most likely to occur immediately after
injection. Visual loss may be accompanied by ophthal-
moplegia and ptosis [2, 3, 5, 6]. Although recovery from
ophthalmoplegia and ptosis is observed in the majority of
cases, vision loss is usually permanent. From 47 cases of
ocular complications following autologous fat injections
reported in the English language literature up to 2015, 38
cases resulted in complete vision loss [5]. In 5 cases, some
remaining visual acuity was observed, varying from light
perception to 20/40 at follow-up, but no improvement was
observed in any of the reported cases, despite the appli-
cation of various management strategies [5]. Although
several treatment options have been proposed and reported
[1, 2, 5, 6], until now no treatment has been proved to be
effective. As results are usually unsatisfactory, there is
little to no evidence for improvement with any proposed
treatment. Therefore, we present here a report of a case of
visual acuity recovery from complete visual loss with no
light perception caused by ophthalmic artery occlusion of
the right eye following autologous fat injection in the facial
area.
Case Presentation
A 38-year-old male with a posttraumatic defect of the
squamous part of the forehead bone underwent soft tissue
augmentation with autologous fat injection in his left
supraorbital and right forehead area. Two years earlier, the
patient had been hit by a piece of wood during work and
suffered a bilateral fracture of the anterior cranial fossa and
bilateral naso-orbital fracture. He underwent microplate
osteosynthesis of the naso-orbital fractures as well as repair
of the dura mater of the anterior cranial fossa. Eighteen
months after the accident, the patient received his first
autologous fat injection into his right forehead and
supraorbital area with no intraoperative or postoperative
complications. The patient was content with the esthetic
results of the first procedure and wanted a second one to
improve the results. The procedure was performed under
local anesthesia (lidocaine with norepinephrine) with
Byron Medical instrumentation. After infiltration of the
donor’s abdominal area with the LAMISTM Infiltration
Cannula (14 ga outer diameter, 30 cm length), autologous
fat was harvested with COLEMANTM Aspiration Cannula
(11 ga outer diameter, 15 cm length) using the lipoaspi-
ration technique and prepared with the standard procedure.
Fat was subcutaneously injected with the COLEMANTM
Style Mini Infiltration Cannula (20 ga outer diameter,
3.175 cm length) and a 2-ml injecting syringe. Through
two small incisions in the right forehead and supraorbital
area, 5 ml of fat was injected into the left supraorbital area
and 5 ml into the right forehead area. No scar release
maneuvers were performed. During the injection of the
final 0.5 ml of fat into the right forehead area, the patient
reported ocular pain and flashes of light in front of the right
eye, followed by a complete visual loss with no light
perception in the right eye. Since occlusion of the right
ophthalmic artery was suspected, the patient was immedi-
ately transferred to the Ophthalmology Ward. On exami-
nation, no light perception and a relative afferent pupillary
defect in the right eye were observed. Fundus examination
of the right eye showed pale, diffused edema of the retina
and severely narrowed retinal arterioles with poor perfu-
sion. Multiple shiny particles were observed within the
lumen of the arteries, consistent with fat embolism. Oph-
thalmic artery occlusion of the right eye was diagnosed.
Treatment was administered immediately. The time from
the first symptoms to the beginning of treatment was less
than 20 min. The administered treatment included pro-
longed circular digital and contact lens-induced ocular
massage, ocular drops: 0.5% timolol, brimonidine and
dorzolamide to the right eye, 24 mg dexamethasone
intravenously, 500 ml of 20% mannitol intravenously,
80 ml of 40% glycerol per os, 500 mg of acetazolamide per
os. Computed head tomography with contrast did not
reveal any new pathologies apart from the preexisting fluid
hypodense areas localized in the right frontal lobe with the
partial defect of the squamous part of the forehead bone
caused by the prior trauma. Slow visual recovery was
observed within 90 min. Examination of the fundus of the
right eye performed after 150 min from the first symptoms
revealed patchy areas of retinal edema and partially per-
fused retinal arteries. At that time, the patient reported
multiple irregular visual field deficits. Further treatment
included alprostadil (Prostavasin) 40 mcg administered
intravenously (with the mean arterial pressure assessment
every 15 min during the intravenous infusion) once a day
for 6 days, dexamethasone intravenously in decreasing
dosages scheme (2 9 8 mg on the second day, 3 9 4 mg
on the third day, 3 9 2 mg on the fourth day).
The patient was discharged on the sixth day after the
visual loss in good local and general condition. The best
corrected visual acuity in the right eye improved to 0.1
logMAR. The standard automated perimetry showed
irregular visual field deficits, and optical coherence
tomography (OCT) revealed significant damage to the
ganglion cell complex (GCC). Pharmacotherapy, with oral
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5 mg vinpocetine daily, was continued after discharge. In
the 2-year follow-up, visual acuity has remained stable,
visual field examination has shown no visual deficits, and
OCT has shown no further decrease in GCC.
Discussion
Visual loss is one of the most severe complications
reported in patients undergoing facial filler injections. In
the majority of reported cases, visual deterioration was
severe and irreversible [2, 5, 7]. Autologous fat injections
are associated with the most severe visual impairment
[2, 5, 8, 9]. Due to differences in particle size among the
different types of facial fillers, patients with ocular symp-
toms following other types of fillers, e.g., hyaluronic acid
injections, are more likely to suffer from localized ocular
occlusion with milder clinical manifestations and better
visual prognosis than patients who received autologous fat
injections [5, 8–10]. Preventative strategies proposed in the
literature to reduce the risk of vascular complications fol-
lowing facial filler injections include: using small-diameter
blunt flexible cannulas or non-traumatic blunt tip needles
instead of sharp cannulas and needles, limiting syringe size
to 1 ml, aspirating before injection, injecting the filler
slowly with minimal pressure, limiting the amount of filler
to less than 0.1 ml with each pass, mixing the filler with
vasoconstrictor, using a topical vasoconstrictor before
injection and moving the needle tip while injecting
[5, 7, 11, 12]. Avoiding injection at the sites of previous
trauma, or at sites with chronic inflammation or scarring, is
also advised. Facial filler injections in patients who have
previously undergone facial or plastic surgeries should be
performed with extra caution [5–7].
According to the literature, no fully effective treatment
is available. Nevertheless, there are several papers pre-
senting various treatment modalities that recover some
degree of visual function. The aim of the treatment after
facial filler embolism is to restore the perfusion of the
retina as soon as possible. The retina is very sensitive to
hypoxia, and after 90 min damage due to retinal ischemia
becomes permanent [1, 3, 5, 7, 13]. Most previously
reported cases of vision loss secondary to fat embolism
have remained without any improvement. Therefore, no
evidence-based treatment strategies are available. Slightly
better outcomes have been reported in cases of vision loss
following injection of fillers other than autologous fat
[5, 7]. From 23 cases of ocular complications following
injections of hyaluronic acid into the facial area, permanent
vision loss was observed in 9 cases, and in 6 cases some
level of improvement in visual acuity was reported [5].
Treatment is aimed at lowering intraocular pressure to
boost retinal perfusion, dilating arteries to eliminate
embolus and reducing the inflammatory component of the
injury. To decrease intraocular pressure, eye drops are
administered (e.g., alpha agonists, B-blockers, carbonic
anhydrase inhibitors) and ocular massage and anterior
chamber paracentesis are performed. Carbon dioxide and
oxygen inhalation or vasodilatory agents such as pros-
taglandin E1 provoke arterial dilation. Hyperbaric oxygen
therapy and systemic corticosteroids decrease the inflam-
matory response. [1–3, 5, 6, 13]. Table 1 presents the
currently recommended treatments and their underlying
mechanism of action.
The crucial factor in the management strategy is the
immediate assessment and referral to the specialist in the
nearby area, preferably an ophthalmologist or retina spe-
cialist, to start the proper treatment within the 90-min time
span after which the damage to the retina is irreversible
[10, 13]. Loh et al. [13] have proposed a treatment algo-
rithm for managing vision loss following filler injections.
When a patient presents the first symptoms of vascular
compromise in the retina, filler injection should be
instantly stopped and the patient should be laid in a supine
position. Immediate treatment (including topical instilla-
tion of timolol, and/or oral acetazolamide and ocular
massage) should be administered by a non-ophthalmologist
injector before arranging and transferring the patient to a
specialist for a definitive therapy, which consists of further
medical administration and—when indicated—anterior
chamber paracentesis. In cases of hyaluronic acid-induced
vision loss, hyaluronidase may be used to dissolve hya-
luronic acid emboli [1–14]. After these acute measures
have been taken, additional supportive therapy (corticos-
teroids, hyperbaric oxygen therapy, anticoagulants) should
be introduced to protect retinal cells.
In our case, treatment was started within 20 min of the
first symptoms of vision loss. The successful outcome can
also be ascribed to the comprehensiveness of the treatment
aimed at restoring perfusion of the retina with the use of
multiple drugs and management strategies. In previously
reported cases, the treatment provided has usually been
incomplete, since the majority of patients suffering from
ocular complications received at most a 3-step therapy
[6, 7]. As noted by Chen et al. [7], combination therapy
may contribute to recovery of visual symptoms. In our
case, in addition to commonly used treatment options such
as ocular massage, acetazolamide, mannitol and corticos-
teroids, we also used alprostadil and vinpocetine. Alpros-
tadil is a synthetic variant of prostaglandin E1. It causes
vasodilatation through directly affecting the vascular
smooth muscles and increases blood flow in the retina.
Alprostadil also decreases thrombocyte activation,
improves cell metabolism by increasing oxygen supply to
the tissues and decreases neutrophil activation and the
release of their toxic metabolites, helping to reduce tissue
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damage caused by inflammation and possibly by hypoxia.
The use of prostaglandin E1 as a part of comprehensive
therapy for visual loss following hyaluronic acid injection
was also reported by Chen et al. [7] and resulted in
improvement in visual acuity, extraocular movement and
visual field defects. Vinpocetine, chemically known as
ethyl apovincamine, is a vinca alkaloid that increases
cerebral blood flow and has neuroprotective effects [16].
This drug is used in the treatment of ischemic cere-
brovascular diseases and vascular dementias. Vinpocetine
may help to increase retinal perfusion and prevent further
damage to still-viable central retinal tissue.
Conclusions
The common use of facial injections, most often performed
in esthetic medicine, has resulted in an increased number of
ocular complications. In the presented case, after autolo-
gous fat injection the patient suffered from sudden com-
plete vision loss in one eye. Fundus examination and
specific symptoms enabled a diagnosis of ophthalmic
artery occlusion. Immediate ophthalmological intervention
and comprehensive therapy with prostaglandins and vin-
pocetine made it possible to restore retinal perfusion and
achieve complete recovery of visual acuity. Awareness of
iatrogenic artery occlusions associated with facial fillers
and the need for immediate treatment should be
popularized among injectors to prevent devastating con-
sequences such as permanent vision loss.
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